IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury

J Immunol. 2003 May 1;170(9):4759-66. doi: 10.4049/jimmunol.170.9.4759.

Abstract

TNF-alpha release and action are central in the pathogenesis of the local and systemic inflammatory responses that occur after intestinal reperfusion. In this study we examined whether IL-1 participated in the cascade of events leading to TNF-alpha production and TNF-alpha-mediated injury following reperfusion of the ischemic superior mesenteric artery in rats. Blockade of the action of IL-1 by the use of anti-IL-1 antiserum or administration of IL-1R antagonist (IL-1ra), a natural antagonist of IL-1Rs, resulted in marked enhancement of reperfusion-associated tissue injury, TNF-alpha expression, and lethality. In contrast, there was marked decrease in IL-10 production. Facilitation of IL-1 action by administration of anti-IL-1ra, which antagonizes endogenous IL-1ra, or exogenous administration of rIL-1beta suppressed reperfusion-induced tissue pathology, TNF-alpha production, and lethality, but increased IL-10 production. Exogenous administration of IL-10 was effective in preventing the increase in tissue or plasma levels of TNF-alpha, the exacerbated tissue injury, and lethality. An opposite effect was observed after treatment with anti-IL-10, demonstrating a role for endogenous production of IL-10 in modulating exacerbated reperfusion-associated tissue pathology and lethality. Finally, pretreatment with anti-IL-10 reversed the protective effect of IL-1beta on reperfusion-associated lethality. Thus, IL-1 plays a major role in driving endogenous IL-10 production and protects against the TNF-alpha-dependent systemic and local acute inflammatory response following intestinal reperfusion injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / antagonists & inhibitors
  • Adjuvants, Immunologic / physiology
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / antagonists & inhibitors
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Inflammation / immunology
  • Inflammation / pathology
  • Inflammation / prevention & control
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / administration & dosage
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / physiology*
  • Interleukin-1 / therapeutic use
  • Interleukin-10 / administration & dosage
  • Interleukin-10 / biosynthesis*
  • Interleukin-10 / physiology
  • Interleukin-10 / therapeutic use
  • Intestinal Mucosa / metabolism
  • Intestines / blood supply*
  • Intestines / immunology
  • Intestines / pathology*
  • Male
  • Mesenteric Artery, Superior / physiopathology
  • Rats
  • Rats, Wistar
  • Receptors, Interleukin-1 / administration & dosage
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / antagonists & inhibitors
  • Recombinant Proteins / therapeutic use
  • Reperfusion Injury / immunology*
  • Reperfusion Injury / pathology*
  • Reperfusion Injury / prevention & control
  • Sialoglycoproteins / administration & dosage
  • Sialoglycoproteins / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Adjuvants, Immunologic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Receptors, Interleukin-1
  • Recombinant Proteins
  • Sialoglycoproteins
  • Tumor Necrosis Factor-alpha
  • Interleukin-10